Puma Biotechnology

Douglas Hunt, B.Sc (Hons).
Senior Vice President, Regulatory Affairs, Pharmacovigilance, Medical Affairs and Law

Mr. Hunt joined Puma Biotechnology as Senior Vice President of Regulatory Affairs, Medical Writing and Project Management in January 2018. Mr. Hunt has over 25 years of regulatory affairs experience and was a regulatory affairs consultant to Puma from February 2017 to January 2018.

Mr. Hunt previously served as Vice President Regulatory Affairs and Quality Assurance at ArmaGen Inc., from March 2015 to December 2017, where he supported the development of multiple products designed to cross the Blood Brain Barrier. He served as Vice President Global Regulatory Affairs (Bioscience) at Baxter International from 2008 to 2015. During his tenure at Baxter, he was responsible for global regulatory affairs for several franchises including oncology. Notably, he supported the successful U.S. advisory Committee that supported the approval of HyQuvia. From March 2000 to July 2008, Mr. Hunt held various roles at Amgen, including as Executive Director, Therapeutic Area Head (Oncology) and Executive Director, Therapeutic Area Head (Bone/Oncology), Global Regulatory Affairs and Safety. During his tenure at Amgen, he supported the development and approval of Neulasta, Aranesp, Enbrel and NPlate. Prior to joining Amgen, Mr. Hunt worked for Quintiles, providing regulatory support to multiple development programs.

Mr. Hunt received a B.Sc (Hons). from the University of Portsmouth (UK). He is a Fellow of the Regulatory Affairs Professionals Society.